Climb Bio (NASDAQ:CLYM) Issues Earnings Results, Misses Expectations By $0.06 EPS

Climb Bio (NASDAQ:CLYM) released its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06), Zacks reports.

Climb Bio Stock Down 2.8%

CLYM stock opened at $7.18 on Friday. The stock has a 50-day simple moving average of $5.20 and a two-hundred day simple moving average of $3.32. Climb Bio has a twelve month low of $1.05 and a twelve month high of $7.59. The firm has a market capitalization of $489.53 million, a PE ratio of -8.07 and a beta of -0.25.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research note on Wednesday, January 21st. Piper Sandler began coverage on shares of Climb Bio in a research note on Friday, February 13th. They set an “overweight” rating on the stock. Robert W. Baird raised their price objective on shares of Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a report on Friday. Wall Street Zen lowered shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. Finally, HC Wainwright boosted their target price on shares of Climb Bio from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Climb Bio has an average rating of “Moderate Buy” and an average price target of $10.60.

Key Stories Impacting Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Wedbush initiated coverage with an “outperform” rating and a $12 price target, providing analyst endorsement that implies significant upside from current levels. Wedbush Initiates Coverage
• Positive Sentiment: Robert W. Baird raised its price target from $9 to $12 and assigned an “outperform” rating, echoing bullish analyst sentiment and adding upward price-target momentum. Baird Price Target Raise
• Positive Sentiment: Company operational update: dosing completed in a Phase 1 subcutaneous study of budoprutug, multiple clinical trials ongoing (pMN, ITP, SLE) with initial data expected H1–H2 2026, ongoing enrollment in CLYM116 Phase 1; management says cash runway extends into 2028 — these milestones support medium-term value if data readouts are positive. Press Release
• Neutral Sentiment: Short-interest reports in early March show zero reported short positions and a 0.0 days-to-cover figure, which appears to be a data anomaly (NaN/inconsistent reporting) and likely has limited informational value until clarified.
• Negative Sentiment: Climb reported Q4 EPS of ($0.26), missing the consensus ($0.20) by $0.06 — a clear near-term negative that likely pressured the stock as investors digest lower-than-expected profitability metrics. Earnings Release

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 101,462 shares of the stock in a transaction dated Friday, December 12th. The shares were purchased at an average cost of $2.86 per share, with a total value of $290,181.32. Following the completion of the acquisition, the director owned 3,396,318 shares in the company, valued at $9,713,469.48. This represents a 3.08% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have bought 321,672 shares of company stock valued at $779,626 over the last quarter. Corporate insiders own 0.80% of the company’s stock.

Hedge Funds Weigh In On Climb Bio

Hedge funds have recently bought and sold shares of the company. MPM Bioimpact LLC purchased a new stake in Climb Bio in the 4th quarter worth approximately $10,686,000. Price T Rowe Associates Inc. MD boosted its holdings in Climb Bio by 265.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock valued at $7,695,000 after purchasing an additional 1,396,722 shares during the period. ADAR1 Capital Management LLC grew its position in shares of Climb Bio by 972.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock valued at $5,730,000 after purchasing an additional 1,298,945 shares in the last quarter. Sphera Funds Management LTD. increased its holdings in shares of Climb Bio by 114.4% in the fourth quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock worth $3,729,000 after purchasing an additional 497,410 shares during the period. Finally, Shay Capital LLC increased its holdings in shares of Climb Bio by 107.5% in the second quarter. Shay Capital LLC now owns 415,000 shares of the company’s stock worth $515,000 after purchasing an additional 215,000 shares during the period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.